Skip to main content
. 2021 Jul 29:298–305. doi: 10.1159/000517559

Table 2.

Unadjusted univariate logistic regression analysis for death as outcome after COVID-19 for the entire cohort of KTxs, and by waves

All patients (n = 182)
First wave (n = 33)
Second wave (n = 149)
OR [95% CI] p value OR [95% CI] p value OR [95% CI] p value
Age (years) 1.06 [1.02–1.11] 0.006 1.08 (0.98–1.18) 0.114 1.06 (1.01–1.11) 0.030
Male 0.93 [o.41–2.08] 0.855 0.53 (0.1–2.88) 0.459 1.04 (0.41–2.65) 0.932
BMI (kg/m3) 1.02 [0.92–1.12] 0.716 1.01 (0.8–1.27) 0.933 1.1 (0.91–1.13) 0.798
Months after transplant 1.00 [0.997–1.01] 0.324 1 (0.99–1.01) 0.775 1 (1–1.01) 0.311
CCI
 2 (reference) 0.031 0.156 0.101
 3 or 4 3.66 [1.30–10.32] 0.014 4.23 (0.43–41.87) 0.217 3.49 (1.09–11.17) 0.036
 5+ 4.52 [1.23–16.61] 0.023 22 (0.94–515.87) 0.055 3.31 (0.74–14.76) 0.116
eGFR at baseline 0.95 [0.93–0.97] <0.001 0.94 (0.89–0.99) 0.029 0.95 (0.92–0.97) <0.001
Obesity 1.01 [0.38–2.69] 0.985 0.45 (0.05–4.46) 0.497 1.24 (0.42–3.7) 0.694
Hypertension 4.54 [1.03–19.96] 0.045 807,737,446.81 (0–0) 0.999 2.86 (0.63–12.98) 0.172
Diabetes 1.18 [0.50–2.77] 0.712 5.25 (0.91–30.22) 0.063 0.72 (0.25–2.09) 0.549
Antiviral
 None (reference) 0.334 0.657 0.335
 Antiretrovirals 2.37 [0.75–7.49] 0.142 1.33 (0.19–9.27) 0.771 3.07 (0.69–13.6) 0.140
 Remdesivir/favipiravir 1.28 [0.49–3.33] 0.608 2.67 (0.33–21.73) 0.360 1.1 (0.37–3.28) 0.871
Immunomodulatory 0.97 [0.37–2.57] 0.948 0.36 (0.06–2.15) 0.263 1.26 (0.39–4.14) 0.700
Corticosteroids 1.28 [0.59–2.80] 0.529 0.42 (0.07–2.53) 0.346 1.77 (0.73–4.33) 0.209
Anticoagulants 1.95 [0.82–4.64] 0.132 0.95 (0.15–5.99) 0.954 2.19 (0.81–5.94) 0.122
ACE inhibitors/ARB 1.17 [0.44–3.08] 0.758 1.33 (0.13–14.01) 0.811 1.08 (0.37–3.15) 0.893

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CCI, Charlson comorbidity index; eGFR, estimated glomerular filtration rate; BMI, body mass index; KTx, kidney transplant recipient.